Company: EDSA
Filing Date: 2025-07-25
Form Type: S-3
Source: 0001171843-25-004721
Chunk: 9

Company: Edesa Biotech, Inc.
Filing Date: 2025-07-25
Form: S-3
Chunk 9
---
, 150
Series A- 1 Shares (as defined below) outstanding and 834 Series B-1 Shares (as defined below). This description is summarized from,
and qualified in its entirety by reference to, our Amended and Restated Articles (as amended, our “Articles”) and our Notice
of Articles, which are filed as exhibits to the registration statement of which this prospectus forms a part.

Common Shares

The holders of our common shares are entitled to one vote for each share held of record on all matters submitted to a vote of the shareholders. Our shareholders do not have cumulative voting rights in the election of directors. The holders of common shares are entitled to receive ratably only those dividends as may be declared by our board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, holders of our common shares are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any outstanding preferred shares. Holders of common shares have no preemptive or other subscription or conversion rights. There are no redemption or sinking fund provisions applicable to our common shares. Common shares outstanding, and to be issued, are, and will be, fully paid and non-assessable. Additional shares of authorized common shares may be issued, as authorized by our board of directors from time to time, without shareholder approval, except as may be required by the Nasdaq Capital Market.

Preferred Shares

Pursuant to our Articles and the
provisions of the British Columbia Business Corporations Act, our board of directors has the authority, without further action
by the shareholders (unless such shareholder action is required by applicable law or the rules of the Nasdaq Capital Market), to designate
and issue an unlimited number of preferred shares in one or more series, to establish from time to time the number of shares to be included
in each such series, to fix the designations, powers, preferences and rights of the shares of each wholly unissued series, and any qualifications,
limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of
shares of such series then outstanding. Preferred shares, if issued, will be fully paid and non-assessable.

The board of directors’ authority to determine the terms of any such preferred shares include, without limitation: (i) the designation of each series and the number of preferred shares that will constitute each such series; (ii) the dividend rate or amount, if any